|
WO2013039785A2
|
|
Heterocyclic inhibitors of histamine receptors for the treatment of disease
|
|
US2011237599A1
|
|
Heterocyclic inhibitors of histamine receptors for the treatment of disease
|
|
TW201204727A
|
|
Heterocyclic inhibitors of histamine receptors for the treatment of disease
|
|
TW201200518A
|
|
Heterocyclic inhibitors of histamine receptors for the treatment of disease
|
|
CA2735368A1
|
|
Aminopyrimidine inhibitors of histamine receptors for the treatment of disease
|
|
CA2735369A1
|
|
Heterocyclic inhibitors of histamine receptors for the treatment of disease
|
|
US2009062253A1
|
|
Heterocyclodiazepine cannabinoid receptor modulators for treatment of disease
|
|
WO2009029617A1
|
|
Diarylamine-substituted quinolones useful as inducible nitric oxide synthase inhibitors
|
|
WO2009029625A1
|
|
4- [heterocyclyl-methyl] -8-fluoro-quinolin-2-ones useful as nitric oxide synthase inhibitors
|
|
WO2009029592A1
|
|
Heterobicyclic-substituted quinolones useful as nitric oxide synthase inhibitors
|
|
US2009105124A1
|
|
Heterocyclic modulators of tgr5
|
|
WO2010016846A1
|
|
Heterocyclic modulators of tgr5 for treatment of disease
|
|
US2009054304A1
|
|
Heterocyclic modulators of tgr5 for treatment of disease
|
|
US2009209536A1
|
|
Aminoquinazoline cannabinoid receptor modulators for treatment of disease
|
|
WO2008103615A1
|
|
Isoquinolines useful as inducible nitric oxide synthase inhibitors
|
|
US2008221161A1
|
|
Heterocyclic modulators of tgr5 for treatment of disease
|
|
WO2008091863A1
|
|
Sulfonyl-substituted bicyclic compounds as ppar modulators for the treatment of non-alcoholic steatohepatitis
|
|
US2010202927A1
|
|
Multi-well plate lid with protective skirt
|
|
WO2008086176A2
|
|
Topical pharmaceutical formulation comprising an inos inhibitor for the treatment of disease
|
|
WO2008073733A1
|
|
Salts of inhibitors of histone deacetylase for the treatment of disease
|
